HRT FORMULATION

PROBLEM TO BE SOLVED: To provide novel medical formulations used in hormone replacement therapy (HRT), for treatment of progestogen-responsive syndromes.SOLUTION: This invention relates to a medical formulation comprising 0.5 mg of estradiol or hydrate thereof and 0.1 mg of norethindrone acetate or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	JENSEN BENTE MOELLER, EDWARDS MARTIN WILLIAM, SHALMI MICHAEL
Format:	Patent
Sprache:	eng ; jpn
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PROBLEM TO BE SOLVED: To provide novel medical formulations used in hormone replacement therapy (HRT), for treatment of progestogen-responsive syndromes.SOLUTION: This invention relates to a medical formulation comprising 0.5 mg of estradiol or hydrate thereof and 0.1 mg of norethindrone acetate or an equivalent amount of norethindrone or an equivalent amount of norethindrone ester or salt. A preferable unit dosage form is a pellet, tablet or capsule having a total weight (excluding capsule or coating) of between about 25 and 125 mg. 【課題】黄体ホルモン反応性症候群を治療するための、ホルモン配置療法（ＨＲＴ）に使用する新規医薬製剤の提供。【解決手段】0.5mgのエストラジオール又はその水和物及び0.1mgのノルエチンドロンアセテート又は対応する量のノルエチンドロン又は対応する量のノルエチンドロンのエステル又は塩を含む医薬製剤。好ましい単位剤形は、(カプセル又はコーティングを除いた)総重量として約25〜125mgを有するペレット、錠剤又はカプセルである。【選択図】なし